Progenics Pharmaceuticals Announces Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
April 20 2017 - 4:05PM
Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company
developing innovative medicines and other products for targeting
and treating cancer, today announced that data from a prospective
biomarker analysis of a Phase 3 study using Progenics’ automated
bone scan index (aBSI) will be presented in an oral session at the
upcoming 2017 American Society of Clinical Oncology (ASCO) Annual
Meeting, which will be held from June 2-6, 2017 in Chicago,
Illinois. In addition, a second abstract from a study on
translating the Prostate Cancer Working Group (PCWG) criteria into
a biomarker for prostate cancer will be presented in a poster
session.
The schedule for the presentations at ASCO is as
follows:
Date & Time: Saturday, June
3, 2017, 1:15 PM-4:15 PMSession Title:
Genitourinary (Prostate) CancerSession Type: Oral
Abstract PresentationTitle: Phase 3 prognostic
analysis of the automated bone scan index (aBSI) in men with
bone-metastatic castration-resistant prostate cancer
(CRPC)Abstract No.: 5006
Date & Time: Monday, June
5, 2017, 1:15 PM-4:15 PMSession Title:
Genitourinary (Prostate) CancerSession Type:
Poster SessionTitle: Translating Prostate Cancer
Working Group (PCWG) criteria into a quantitative progression
biomarker in metastatic Castration Resistant Prostate Cancer
(mCRPC)Abstract No.: 5068
About Progenics
Progenics Pharmaceuticals, Inc. develops
innovative medicines and other technologies to target and treat
cancer. The Company's pipeline includes: 1) therapeutic agents
designed to precisely target cancer (AZEDRA® and 1095), 2)
PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM),
and 3) imaging analysis tools. Progenics' first commercial product,
RELISTOR® (methylnaltrexone bromide) for opioid-induced
constipation, is partnered with Valeant Pharmaceuticals
International, Inc.
This press release may contain projections and
other "forward-looking statements" regarding future events.
Statements contained in this communication that refer to Progenics'
estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics'
current perspective of existing trends and information as of the
date of this communication. Forward looking statements generally
will be accompanied by words such as "anticipate," "believe,"
"plan," "could," "should," "estimate," "expect," "forecast,"
"outlook," "guidance," "intend," "may," "might," "will,"
"possible," "potential," "predict," "project," or other similar
words, phrases or expressions. Such statements are predictions
only, and are subject to risks and uncertainties that could cause
actual events or results to differ materially. These risks and
uncertainties include, among others, the cost, timing and
unpredictability of results of clinical trials and other
development activities and collaborations, such as our
collaboration with Valeant on the RELISTOR oral formulation and the
Phase 3 clinical program for 1404; our ability to successfully
integrate EXINI Diagnostics AB and to develop and commercialize its
products; the unpredictability of the duration and results of
regulatory review of New Drug Applications and Investigational
NDAs; market acceptance for approved products; the effectiveness of
the efforts of our partners to market and sell products on which we
collaborate and the royalty revenue generated thereby; generic and
other competition; the possible impairment of, inability to obtain
and costs of obtaining intellectual property rights; possible
product safety or efficacy concerns, general business, financial
and accounting matters, litigation and other risks. More
information concerning Progenics and such risks and uncertainties
is available on its website, and in its press releases and reports
it files with the U.S. Securities and Exchange Commission.
Progenics is providing the information in this press release as of
its date and, except as expressly required by law, Progenics
disclaims any intent or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or circumstances or otherwise.
Additional information concerning Progenics and
its business may be available in press releases or other public
announcements and public filings made after this release. For more
information, please visit www.progenics.com. Please follow us on
LinkedIn®. Information on or accessed through our website or social
media sites is not included in the company's SEC filings.
(PGNX-F)
Contact:
Melissa Downs
Investor Relations
(646) 975-2533
mdowns@progenics.com
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Sep 2023 to Sep 2024